Streptococcus pneumoniae is a known notorious cause of invasive pneumococcal diseases as well as asymptomatic host carriage. Efforts have been made to curb this infectious organism through various vaccine strategies. However, its several strains and serotypes have necessitated various vaccine schedules and updates in the USA and globally. The evolution in pneumococcal vaccine schedules is not without challenges, such as cost, vaccine hesitancy, uptake and global disparities. This narrative review synopsizes the history of the Pneumococcal Vaccine and changes in its schedules in the last two decades based on published data. We focused on the impact of pneumococcal vaccination on invasive pneumococcal diseases, historical limitations, current challenges and future directions. Despite advancements in vaccination against S.pneumoniae infections, some pertinent issues exist that need to be swiftly fixed, to reduce national and thus global burden of pneumococcal diseases.
References
[1]
Gierke, R., Wodi, A.P. and Kobayashi, M. (2021) Pneumococcal Disease. In: Hall, E., Wodi, A.P., Hamborsky, J., Morelli, V., Schillie, S., Eds., EpidemiologyandPreventionofVaccine-PreventableDiseases, 14th Edition, Public Health Foundation, 255-274.
[2]
Noharet-Koenig, R., Lasota, K., Faivre, P. and Langevin, E. (2023) Evolution of Pneumococcal Vaccine Recommendations and Criteria for Decision Making in 5 Western European Countries and the United States. MDMPolicy&Practice, 8. https://doi.org/10.1177/23814683231174432
[3]
World Health Organization (2019) WHO Position Paper: Pneumococcal Conjugate Vaccines in Infants and Children under 5 Years of Age. Weekly Epidemiological Record, 8, 85-104. https://www.who.int/publications/i/item/10665-310968
[4]
Musher, D.M., Anderson, R. and Feldman, C. (2022) The Remarkable History of Pneumococcal Vaccination: An Ongoing Challenge. Pneumonia, 14, Article No. 5. https://doi.org/10.1186/s41479-022-00097-y
[5]
Wodi, A.P. and Morelli, V. (2021) Principles of Vaccination. In: Hall, E., Wodi, A.P., Hamborsky, J., Morelli, V., Schillie, S., Eds., EpidemiologyandPreventionofVaccine-PreventableDiseases, 14th Edition, Public Health Foundation, 1-8. https://www.cdc.gov/vaccines/pubs/pinkbook/prinvac.html
[6]
Savoy, M.L. (2024) Pneumococcal Vaccine. Merck & Co., Inc., Rahway Center for Disease Control.
[7]
Centers for Disease Control and Prevention (2008) Progress in Introduction of Pneumococcal Conjugate Vaccine—Worldwide, 2000-2008. Morbidity and Mortality Weekly Report, 57, 1148-1151. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5742a2.htm
[8]
Chang, Q., Stevenson, A.E., Croucher, N.J., Lee, G.M., Pelton, S.I., Lipsitch, M., etal. (2015) Stability of the Pneumococcal Population Structure in Massachusetts as PCV13 Was Introduced. BMCInfectiousDiseases, 15, Article No. 68. https://doi.org/10.1186/s12879-015-0797-z
[9]
Tahamtan, A., Charostad, J., Hoseini Shokouh, S.J. and Barati, M. (2017) An Overview of History, Evolution, and Manufacturing of Various Generations of Vaccines. JournalofArchivesinMilitaryMedicine. In Press. https://doi.org/10.5812/jamm.12315
[10]
Westerink, M.A.J., Schroeder Jr, H.W. and Nahm, M.H. (2011) Immune Responses to Pneumococcal Vaccines in Children and Adults: Rationale for Age-Specific Vaccination. Aging and Disease, 3, 51-67.
[11]
Center for Disease Control (2024) About Pneumococcal Vaccines. https://www.cdc.gov/vaccines/vpd/pneumo/hcp/about-vaccine.html#print
[12]
Kobayashi, M., Farrar, J.L., Gierke, R., Britton, A., Childs, L., Leidner, A.J., etal. (2022) Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices—United States, 2022. MorbidityandMortalityWeeklyReport, 71, 109-117. https://doi.org/10.15585/mmwr.mm7104a1
[13]
Rudawsky, N. and Mansukhani, R. (2022) The Evolution of Pneumococcal Vaccines and Current Guidelines. https://www.pharmacytimes.com/view/the-evolution-of-pneumococcal-vaccines-and-current-guidelines
[14]
Committee on Infectious Diseases (2010) Recommendations for the Prevention of Streptococcus pneumoniae Infections in Infants and Children: Use of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Pneumococcal Polysaccharide Vaccine (PPSV23). Pediatrics, 126, 186-190. https://doi.org/10.1542/peds.2010-1280
[15]
Wasserman, M., Chapman, R., Lapidot, R., Sutton, K., Dillon-Murphy, D., Patel, S., etal. (2021) Twenty-year Public Health Impact of 7-and 13-Valent Pneumococcal Conjugate Vaccines in US Children. EmergingInfectiousDiseases, 27, 1627-1636. https://doi.org/10.3201/eid2706.204238
[16]
Hsu, K.K., Kellenberg, J.E., Pelton, S.I., Friedman, D.S., Moore, M.R. and Jordan, H.T. (2007) Emergence of Antimicrobial-Resistant Serotype 19A Streptococcus Pneumoniae—Massachusetts, 2001-2006. Morbidity and Mortality Weekly Report, 56, 1077-1080. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5641a2.htm
[17]
Grijalva, C.G. and Pelton, S.I. (2011) A Second-Generation Pneumococcal Conjugate Vaccine for Prevention of Pneumococcal Diseases in Children. CurrentOpinioninPediatrics, 23, 98-104. https://doi.org/10.1097/mop.0b013e328341d1f5
[18]
Micoli, F., Romano, M.R., Carboni, F., Adamo, R. and Berti, F. (2023) Strengths and Weaknesses of Pneumococcal Conjugate Vaccines. GlycoconjugateJournal, 40, 135-148. https://doi.org/10.1007/s10719-023-10100-3
[19]
U.S. Food and Drug Administration (2017) Package Insert-Prevnar 13-FDA. https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/Package-Insert------Prevnar-13.pdf
[20]
Pichichero, M.E. (2017) Pneumococcal Whole-Cell and Protein-Based Vaccines: Changing the Paradigm. ExpertReviewofVaccines, 16, 1181-1190. https://doi.org/10.1080/14760584.2017.1393335
[21]
Li, S., Liang, H., Zhao, S., Yang, X. and Guo, Z. (2023) Recent Progress in Pneumococcal Protein Vaccines. FrontiersinImmunology, 14, Article 1278346. https://doi.org/10.3389/fimmu.2023.1278346
[22]
McDaniel, L.S. and Swiatlo, E. (2021) If Not Now, When? Nonserotype Pneumococcal Protein Vaccines. OpenForumInfectiousDiseases, 8, ofab576. https://doi.org/10.1093/ofid/ofab576
[23]
Duke, J.A. and Avci, F.Y. (2023) Emerging Vaccine Strategies against the Incessant Pneumococcal Disease. npjVaccines, 8, Article No. 122. https://doi.org/10.1038/s41541-023-00715-w
[24]
Hammitt, L.L., Campbell, J.C., Borys, D., Weatherholtz, R.C., Reid, R., Goklish, N., etal. (2019) Efficacy, Safety and Immunogenicity of a Pneumococcal Protein-Based Vaccine Co-Administered with 13-Valent Pneumococcal Conjugate Vaccine against Acute Otitis Media in Young Children: A Phase IIb Randomized Study. Vaccine, 37, 7482-7492. https://doi.org/10.1016/j.vaccine.2019.09.076
[25]
Dunne, E.M., Nunes, M.C., Slack, M.P.E., Theilacker, C. and Gessner, B.D. (2023) Effects of Pneumococcal Conjugate Vaccines on Reducing the Risk of Respiratory Disease Associated with Coronavirus Infection. Pneumonia, 15, Article No. 10. https://doi.org/10.1186/s41479-023-00112-w
[26]
International Vaccine Access Center (IVAC) (n.d.) Johns Hopkins Bloomberg School of Public Health. Vaccine Introduction over Time. VIEW-Hub. https://view-hub.org/vaccine/pcv?set=vaccine-introduction-over-time&group=vaccine-introduction&category=pcv&year=2019
[27]
Conklin, L., Loo, J.D., Kirk, J., Fleming-Dutra, K.E., Deloria Knoll, M., Park, D.E., etal. (2014) Systematic Review of the Effect of Pneumococcal Conjugate Vaccine Dosing Schedules on Vaccine-Type Invasive Pneumococcal Disease among Young Children. PediatricInfectiousDiseaseJournal, 33, S109-S118. https://doi.org/10.1097/inf.0000000000000078
[28]
Mueller, K., Koury, J., Sarangarm, P., Hellinga, R.C., Shenk, E., Stewart, M.B., etal. (2023) Pneumococcal Polysaccharide Vaccination (PPSV23) in High-Risk Pediatric Patients with Diabetes. TheJournalofPediatricPharmacologyandTherapeutics, 28, 417-422. https://doi.org/10.5863/1551-6776-28.5.417
[29]
Committee on Infectious Diseases (2000) Policy Statement: Recommendations for the Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate Vaccine (Prevnar), Pneumococcal Polysaccharide Vaccine, and Antibiotic Prophylaxis. Pediatrics, 106, 362-366. https://doi.org/10.1542/peds.106.2.362
[30]
Esposito, S., Lizioli, A., Lastrico, A., Begliatti, E., Rognoni, A., Tagliabue, C., etal. (2007) Impact on Respiratory Tract Infections of Heptavalent Pneumococcal Conjugate Vaccine Administered at 3, 5 and 11 Months of Age. RespiratoryResearch, 8, Article No. 12. https://doi.org/10.1186/1465-9921-8-12
[31]
Kalin, M. (1998) Pneumococcal Serotypes and Their Clinical Relevance. Thorax, 53, 159-162. https://doi.org/10.1136/thx.53.3.159
[32]
Centers for Disease Control and Prevention (2024) Antibiotic-Resistant Streptococcus Pneumoniae. https://www.cdc.gov/pneumococcal/php/drug-resistance/index.html#:~:text=Vaccine%20impact&text=Pneumococcal%20conjugate%20vaccines%20(PCVs)%20include,IPD%20in%20the%20United%20States
[33]
van Heuvel, L., Paget, J., Dückers, M. and Caini, S. (2023) The Impact of Influenza and Pneumococcal Vaccination on Antibiotic Use: An Updated Systematic Review and Meta-Analysis. AntimicrobialResistance&InfectionControl, 12, Article No. 70. https://doi.org/10.1186/s13756-023-01272-6
[34]
Public Health Agency of Canada (2024) Pneumococcal Vaccines: Canadian Immunization Guide. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-16-pneumococcal-vaccine.html#t3
[35]
Public Health England (2019) Changes to the Infant Pneumococcal Conjugate Vaccine Schedule. PHE Publications. https://assets.publishing.service.gov.uk/media/5de5018940f0b650e4a64d50/PCV_schedule_change_HCP_information.pdf
[36]
Bloom, D.E., Kirby, P.N., Pugh, S. and Stawasz, A. (2020) Commentary: Why Has Uptake of Pneumococcal Vaccines for Children Been So Slow? the Perils of Undervaluation. PediatricInfectiousDiseaseJournal, 39, 145-156. https://doi.org/10.1097/inf.0000000000002521
[37]
World Health Organization (n.d.) Pneumococcal Vaccination Coverage. https://immunizationdata.who.int/pages/coverage/PCV.html?CODE=Global&ANTIGEN=PCV3&YEAR=
[38]
World Health Organization: Department of Immunization, Vaccines and Biologicals. (2014) A Call-to-Action for National Programmes and the Global Community by the WHO Immunization Practices Advisory Committee, Geneva, Switzerland. https://iris.who.int/bitstream/handle/10665/131568/WHO_IVB_14.05_eng.pdf?sequence=1
[39]
Lane, S., MacDonald, N.E., Marti, M. and Dumolard, L. (2018) Vaccine Hesitancy around the Globe: Analysis of Three Years of WHO/UNICEF Joint Reporting Form Data-2015-2017. Vaccine, 36, 3861-3867. https://doi.org/10.1016/j.vaccine.2018.03.063
Médecins Sans Frontières (2017) A Fair Shot for Vaccine Affordability: Understanding and Addressing the Effects of Patents on Access to Newer Vaccines. MSF Report. https://www.msfaccess.org/fair-shot-vaccine-affordability
[42]
Cai, F.Y., Fussell, T., Cobey, S. and Lipsitch, M. (2018) Use of an Individual-Based Model of Pneumococcal Carriage for Planning a Randomized Trial of a Whole-Cell Vaccine. PLOSComputationalBiology, 14, e1006333. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6181404/ https://doi.org/10.1371/journal.pcbi.1006333
[43]
Patel, A.R., Breck, A.B. and Law, M.R. (2018) The Impact of Pharmacy-Based Immunization Services on the Likelihood of Immunization in the United States. JournaloftheAmericanPharmacistsAssociation, 58, 505-514.e2. https://doi.org/10.1016/j.japh.2018.05.011
[44]
Steyer, T.E., Ragucci, K.R., Pearson, W.S. and Mainous, A.G. (2004) The Role of Pharmacists in the Delivery of Influenza Vaccinations. Vaccine, 22, 1001-1006. https://doi.org/10.1016/j.vaccine.2003.08.045
[45]
de Koning, R., Gonzalez Utrilla, M., Spanaus, E., Moore, M. and Lomazzi, M. (2024) Strategies Used to Improve Vaccine Uptake among Healthcare Providers: A Systematic Review. Vaccine:X, 19, Article 100519. https://doi.org/10.1016/j.jvacx.2024.100519
[46]
Cataldi, J.R., Kerns, M.E. and O’Leary, S.T. (2020) Evidence-Based Strategies to Increase Vaccination Uptake: A Review. CurrentOpinioninPediatrics, 32, 151-159. https://doi.org/10.1097/mop.0000000000000843
[47]
Centers for Disease Control and Prevention (CDC) (2013) Progress in Immunization Information Systems—United States, 2011. Morbidity and Mortality Weekly Report, 62, 48-51.
